Park Kyung-Chae, Choi Junwon, Choi Sujin, Lee Gyurim, An Hyun-Ju, Yun Hyerin, Lee Soonchul
Health Promotion Center, CHA Bundang Medical Center, CHA University School of Medicine, 335 Pangyo-ro, Bundang-gu, Gyeonggi-do Zip code: 13488, Republic of Korea.
Department of Molecular Science and Technology, Ajou University, 206 World cup-ro, Yeongtong-gu, Suwon, Gyeonggi 16499, Republic of Korea; Advanced College of Bio-convergence Engineering, Ajou University, 206 World cup-ro, Yeongtong-gu, Suwon, Gyeonggi 16499, South Korea.
Int J Pharm. 2025 Apr 30;675:125568. doi: 10.1016/j.ijpharm.2025.125568. Epub 2025 Apr 7.
Osteoarthritis (OA) affects millions globally, with its prevalence expected to rise due to an aging population. Selenium nanoparticles (SeNPs) have shown therapeutic potential, and polydopamine (PDA) coatings on nanoparticles offered additional benefits, including enhanced biocompatibility, antioxidant properties, and anti-inflammatory effects. However, while SeNPs and PDA have demonstrated efficacy in several disease models, their role in OA remains underexplored. This study aimed to evaluate the therapeutic effects of PDA-coated SeNPs in the treatment of OA. We developed PDA-coated SeNPs (PDA-SeNP) to improve Reactive Oxygen Species (ROS) control and evaluated their anti-inflammatory and cartilage-regenerative effects in both in vitro and in vivo models of OA. Transmission electron microscopy confirmed that the sizes of PDA-SeNPs was 203 ± 11 nm, with PDA coatings of approximately 12 ± 2 nm on the SeNPs. In vitro, treatment with PDA-SeNPs significantly enhanced the expression of cartilage-regeneration markers while reducing inflammatory marker levels in chondrocytes. For the in vivo analysis, OA was induced by injecting monoiodoacetate into the knee joints of rats. Four weeks after treatment with phosphate-buffered saline (PBS, n = 6), SeNPs (n = 6), or PDA-SeNPs (n = 6), the incapacitance test demonstrated improved weight-bearing capacity in the SeNP and PDA-SeNP groups compared to the PBS control. Gross morphological assessment and histological analysis revealed that PDA-SeNPs mitigated cartilage damage more effectively than SeNPs alone. These findings suggest that PDA-SeNPs promote cartilage repair, enhance extracellular matrix synthesis, and reduce knee pain in OA, establishing them as promising candidates for future OA treatment.
骨关节炎（OA）在全球影响着数百万人，随着人口老龄化，其患病率预计还会上升。硒纳米颗粒（SeNPs）已显示出治疗潜力，纳米颗粒上的聚多巴胺（PDA）涂层具有额外的益处，包括增强生物相容性、抗氧化性能和抗炎作用。然而，虽然SeNPs和PDA在几种疾病模型中已证明有效，但它们在OA中的作用仍未得到充分研究。本研究旨在评估PDA包被的SeNPs对OA的治疗效果。我们开发了PDA包被的SeNPs（PDA-SeNP）以改善活性氧（ROS）控制，并在OA的体外和体内模型中评估了它们的抗炎和软骨再生作用。透射电子显微镜证实PDA-SeNPs的尺寸为203±11nm，SeNPs上的PDA涂层约为12±2nm。在体外，用PDA-SeNPs处理可显著增强软骨再生标志物的表达，同时降低软骨细胞中的炎症标志物水平。对于体内分析，通过向大鼠膝关节注射单碘乙酸诱导OA。用磷酸盐缓冲盐水（PBS，n = 6）、SeNPs（n = 6）或PDA-SeNPs（n = 6）治疗四周后，失能测试表明与PBS对照组相比，SeNP组和PDA-SeNP组的负重能力有所改善。大体形态学评估和组织学分析表明，PDA-SeNPs比单独的SeNPs更有效地减轻软骨损伤。这些发现表明，PDA-SeNPs可促进软骨修复，增强细胞外基质合成，并减轻OA患者的膝关节疼痛，使其成为未来OA治疗的有希望的候选药物。
